Sermorelin and Tesamorelin: Approved Medicines, Off-Label Claims, and What the Evidence Shows

Sermorelin and tesamorelin are marketed alongside the popular recovery and anti-aging peptides, but they belong in a different and more credible category: they are real, regulator-approved prescription medicines. That distinction is genuine and worth stating confidently. Both work by stimulating the body's own growth hormone release rather than replacing the hormone directly. Their strongest evidence is tied to their specific approved uses, while much of the wider anti-aging buzz around them is off-label and less established. Here is the balanced picture, starting with how they actually work.

How they work: the mechanism of action

Both sermorelin and tesamorelin are analogs of growth-hormone-releasing hormone (GHRH), the natural signal your hypothalamus uses to tell the pituitary gland to release growth hormone. They are growth-hormone secretagogues: rather than supplying growth hormone directly, they prompt the body to produce more of its own.

Mechanistically, the molecule binds the GHRH receptor on the somatotroph cells of the anterior pituitary. That receptor is a G-protein-coupled receptor; activating it raises intracellular cyclic AMP, which triggers the somatotrophs to synthesize and release growth hormone. The released growth hormone then drives the downstream effects, including production of insulin-like growth factor 1 (IGF-1) in the liver and other tissues.

The important nuance is that this is more physiologic than injecting growth hormone directly. Because the medicine acts one step upstream, it works with the body's own control system: growth hormone is still released in the natural pulsatile pattern, and the normal negative-feedback loops (somatostatin and IGF-1 feedback) remain in place to limit overshoot. That preserved feedback is a meaningful safety and physiology advantage over straight growth hormone replacement, and it is a large part of why these became legitimate medicines.

The two molecules differ in structure, which explains their different profiles:

• Sermorelin is GHRH(1-29), the first 29 amino acids of natural GHRH. This N-terminal fragment is the shortest sequence that retains the full biological activity of the parent hormone, but it is broken down quickly, giving it a short half-life of only a few minutes.
• Tesamorelin (brand name Egrifta) is a stabilized analog of the full GHRH(1-44) sequence, modified with an added trans-3-hexenoic acid group on the N-terminus. That modification protects it from rapid enzymatic breakdown, giving it greater stability and a longer-lasting action, which is what made it suitable as an approved daily injectable.

Why these are different from grey-market peptides

This is the genuinely encouraging part. Both compounds have cleared regulatory review for defined uses:

• Sermorelin is approved by the US Food and Drug Administration and by Australia's Therapeutic Goods Administration. It is not approved by the European Medicines Agency.
• Tesamorelin is approved by the US Food and Drug Administration. It is not approved by the European Medicines Agency or by Australia's Therapeutic Goods Administration.

Approval matters. It means a medicine has been through controlled trials, that there is real safety and efficacy data behind its labeled indication, and that licensed product is quality-controlled rather than made and sold outside a regulated supply chain. Many of the peptides covered in our full peptides guide have none of that. Sermorelin and tesamorelin do.

What tesamorelin is actually approved for

Here is where precision matters. According to PubMed, tesamorelin is approved to reduce excess abdominal fat in patients with HIV-associated lipodystrophy, a condition in which antiretroviral therapy can drive a buildup of deep visceral fat around the organs. A review in Drugs describes it as the first, and at the time only, treatment indicated for reducing excess abdominal fat in this specific patient group.

The evidence behind that indication is solid. In a 12-month randomized, placebo-controlled trial of 404 patients, tesamorelin reduced visceral fat by roughly 18 percent, improved related body composition measures, and was generally well tolerated, with no significant disturbance of glucose. That is a real, measured benefit in a defined population, not a marketing promise.

What it is not is a general fat-loss or body-recomposition drug for the healthy population. Reducing a specific kind of fat in a specific medical condition is a long way from the broad "lean you out and turn back the clock" framing that often surrounds it online.

What sermorelin is used for, and the off-label gap

Sermorelin's established role relates to its approved indication as a growth-hormone secretagogue. Beyond that, the purposes most often promoted to wellness audiences, such as body-fat reduction and connective-tissue healing, are off-label. They borrow the credibility of an approved medicine and stretch it toward outcomes that are far less firmly established.

A 2026 review in Sports Medicine examining approved and unapproved peptide therapies makes the useful point that being an approved medicine for one purpose does not automatically validate every recovery or performance claim attached to it. None of this means the broader uses cannot help anyone; it simply means the evidence for them is thinner than the evidence for the approved indications, and that is worth knowing before you weigh them.

Safety: better characterized, but not risk-free

Because these are studied medicines, their side-effect profiles are reasonably well described. Reported effects for both include facial flushing, headache, dizziness, and hypoglycemia (low blood sugar). In the tesamorelin trials, most serious adverse events were injection-site reactions or effects already known to be associated with growth hormone therapy.

That is a real advantage over unregulated compounds, where the safety picture is often unknown. But "better characterized" is not "no risk." These are medicines that act on the growth hormone axis, so they call for proper medical assessment, including who should not take them, and ongoing monitoring. That is exactly the kind of decision that belongs with a doctor rather than a website.

One practical note: as GHRH analogs they are on the World Anti-Doping Agency Prohibited List, relevant only if you compete in a tested sport.

Our position

Sermorelin and tesamorelin are a genuinely more credible category than grey-market peptides. They have real regulatory approval, real trial data, a characterized safety profile, and quality-controlled product, and they work through a well-understood, physiologic mechanism. That is a solid foundation, and we treat it as one. The strongest evidence lives inside their specific approved indications; the wider anti-aging and body-recomposition claims are off-label and less proven, and are best weighed on their own merits.

Where these medicines are appropriate, the value we add is straightforward: an honest assessment, the correct indication, and proper monitoring of the growth hormone axis over time. That is exactly the kind of decision that belongs with a doctor, in our case a board-certified endocrinologist, who can judge whether a GHRH analog fits your situation and manage it properly. This article is educational and is not an offer to prescribe or supply any medicine.

If you are weighing other recovery compounds, we have written companion honest reviews, including BPC-157 for injury recovery, what the evidence actually shows.